You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Distributed REMD Simulation for Probing Alzheimer Molecular Mechanisms
SBC: PARABON COMPUTATION, INC. Topic: NIADESCRIPTION (provided by applicant): PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Immunoassay for diagnosis of invasive fungal disease
SBC: Immuno-mycologics, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Early diagnosis of infectious disease is critical to patient outcome. An important early question is - is it a fungus, a bacterium or a virus? A rapid answer to this question would allow preemptive treatment that cansave lives. The goal of this project is a rapid and inexpensive immunoassay that will use serum as a sample to broadly identify the presence of ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel LANCL2-based Anti-diabetic Compounds
SBC: Biotherapeutics, Inc. Topic: NIDDKDESCRIPTION (provided by applicant): About 28.3 million Americans have type II diabetes (T2D) and over 40.1% of middle-aged adults have prediabetes, a condition characterized by impaired glucose tolerance and insulin resistance. Current antidiabetic medications are effective in improving insulin sensitivity, but their chronic administration has significant side effects suc as cardiovascular compli ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Enhanced bioscavenger for medical countermeasures against organophosphorus agents
SBC: LUNA INNOVATIONS INCORPORATED Topic: NIEHSDESCRIPTION (provided by applicant): Counteracting the threat of intoxication by organophosphorus nerve agents (OP's) is an important mission for homeland security as well as for treating workers exposed to pesticides. OP's act on acetylcholinesterase to prevent synaptic inactivation, thereby leading to immobilization and death on sustained application. Currently, the most promising stra ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A Thermo-responsive Biopharmaceutical to Enhance the Tear Production of Lacritin
SBC: EYERX RESEARCH, INC. Topic: NEIProject Summary/Abstract Ocular pharmaceuticals predominantly use the topical route of administration, which involves a number of benefits and limitations when compared to systemic drug routes. A major limitation of the ocular topical route is the rapid loss of drug via tearing and nasolacrimal drainage, requiring the use of frequent dosing and high drug concentrations that then create formulation ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Nanoparticle scavengers for medical countermeasures against mycotoxin
SBC: LUNA INNOVATIONS INCORPORATED Topic: NIGMSDESCRIPTION (provided by applicant): Mycotoxin is naturally occurring and is a toxic small molecule produced by fungi. These fungal toxins are representative of a large number of lipophilic agents that pose significant acute and chronic dangers to militarycombatants as potential warfare agents. There are many examples of mycotoxins, some more acutely potent than others. Mycotoxin is classified as ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema
SBC: Covenant Therapeutics LLC Topic: NHLBIDESCRIPTION (provided by applicant): The objective of this proposal is to exploit a newly discovered anti-inflammatory function involving the aminopeptidase activity of the leukotriene A4 hydrolase for the treatment of pulmonary emphysema. The leukotrieneA4 hydrolase is a dual-functioning enzyme with dichotomously opposing functions. As an epoxide hydrolase, it catalyzes the conversion of leukotri ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of the Antigenicity of Black Restricted FVIII Haplotypes and Haplotype
SBC: Haplomics Topic: NIMHDEvaluation of the Antigenicity of Black-Restricted Haplotypes of Factor VIII ABSTRACT About 30% of congenital Hemophilia A (HA) patients develop alloantibodies that neutralize the activity of replacement Factor (F) VIII proteins. Such patients, who are termed inhibitor patients, are typically treated with so called bypassing agents such as recombinant (r) FVIIa and FEIBA. Bypassing agents are mor ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Interactive Technology for Hearing Aid Education and Acceptance
SBC: Healthcare Technologies and Methods, LLC Topic: NIAABSTRACT More than 20 million elderly people in the US have significant hearing loss but only 20% use hearing aids. Of these, 35 - 50% are dissatisfied with them, which often results in the hearing aids being returned within the trial period or left in-the-drawer . With untreated hearing loss resulting in a 200% - 300% increase in the risk of dementia, depression, and falls, and severe communicat ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
System for multidimensional analysis of growth and migration of neurons and neuro
SBC: Inhibikase Therapeutics, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Inhibikase Therapeutics is a clinical stage, biopharmaceutical company that has developed a host- targeted mechanism of action to treat AIDS-related and drug-induced progressive multifocal leukoencephalopathy (PML). PMLis a demyelinating disease of the central nervous system and was rarely seen clinically until the era of the HIV epidemic began in the mid-1980s ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health